New recommendations on health care worker exposure to HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


New recommendations on health care worker exposure to HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

STEP Perspect. 1996 Fall;8(3):8-10. Unique Identifier : AIDSLINE AIDS/97702552
Woodward J; University of Washington, Seattle, WA.


Abstract: Health care workers who deal with HIV patients are trained and knowledgeable in universal precautions. However, they remain at risk of seroconversion from accidental exposure, and new treatment options are highlighted. Theories on viral dynamics and aggressive antiretroviral regimens suggest that health care workers receive post exposure prophylaxis. Risk factors are identified; needlesticks, which are thought to be the most risky, result in seroconversion only 0.2 to 0.3 percent of the time.
Keywords: Anti-HIV Agents/THERAPEUTIC USE Disease Transmission/*PREVENTION & CONTROL Drug Therapy, Combination Guidelines HIV/*DRUG EFFECTS HIV Infections/DRUG THERAPY/*PREVENTION & CONTROL/*TRANSMISSION HIV Protease Inhibitors/THERAPEUTIC USE *Health Personnel Human Indinavir/THERAPEUTIC USE Lamivudine/THERAPEUTIC USE Occupational Exposure/*PREVENTION & CONTROL Risk Factors Viral Load Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLEKWDanti-hivagents/therapeuticusediseasetransmission/KWDprevention&controldrugtherapy,combinationguidelineshiv/KWDdrugeffectshivinfections/drugtherapy/KWDprevention&control/KWDtransmissionhivproteaseinhibitors/therapeuticuseKWDhealthpersonnelhumanindinavir/therapeuticuselamivudine/therapeuticuseoccupationalexposure/KWDprevention&controlriskfactorsviralloadzidovudine/therapeuticusenewsletterarticle
970830
M9781199

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .